Business Wire

SpeeDx Receives CE-IVD Mark for PlexPCR® SARS-CoV-2

26.4.2021 10:00:00 EEST | Business Wire | Press release

Share

SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its Plex PCR ® SARS-CoV-2* assay – a two gene test for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. The high-throughput test is compatible with 96- or 384-well qPCR systems and liquid handling robotics to support a streamlined laboratory workflow and accelerate time to result.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210426005269/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The PlexPCR® SARS-CoV-2 assay targets two highly conserved regions of the SARS-CoV-2 genome. Designed and tested against a database of over 1,000,000 sequences, the performance of the PlexPCR® SARS-CoV-2 assay can detect all known circulating variants. The high-throughput test is compatible with 96- or 384-well qPCR systems and liquid handling robotics to support a streamlined laboratory workflow and accelerate time to result. (Photo: Business Wire)

“The COVID-19 pandemic has impacted testing laboratories throughout the world as many diagnostic supply companies have struggled to meet testing needs,” said SpeeDx CEO Colin Denver. “This has disrupted supply chains and impacted efficiency across the board. SpeeDx has the advantage of not needing to manufacture target-specific, expensive, and time-consuming testing probes. Our unique technology has allowed us to bulk produce and stockpile universal raw materials, so we are able to rapidly fulfill all our current customers’ orders while having the capacity to supply many more large-volume testing laboratories.”

The Plex PCR® SARS-CoV-2 assay targets two highly conserved regions of the SARS-CoV-2 genome (RdRp and ORF1ab). Designed and tested against a database of over 1,000,000 sequences, the performance of the Plex PCR® SARS-CoV-2 assay can detect all known circulating variants§. Regular computer-based analysis is performed to ensure new, emerging variants of the SARS-CoV-2 virus can be effectively detected, without the need for confirmatory testing.

The Plex PCR® SARS-CoV-2 assay has compatible workflow with the Plex PCR® RespiVirus test, a two-well multiplex assay for the detection of 14 targets from 11 viral respiratory-illness causing pathogens including Influenza A, Influenza B, and Respiratory Syncytial Viruses (A & B). Both respiratory tests are also compatible with the SpeeDx Plex Prep™ - a compact and cost-effective liquid handling system. The combination of Plex Prep™ robotics and automated software analysis can support a scalable workflow for throughputs of 480 to 1,920 patient samples in an 8-hour shift. A respiratory bacteria test is due for launch later this year to complete SpeeDx’s respiratory infectious disease test portfolio.

The addition of Plex PCR® SARS-CoV-2 broadens SpeeDx’s available testing menu from the current suite of tests for sexually transmitted infections and antimicrobial resistance markers that include Resistance Plus ® MG and Resistance Plus ® GC – supporting Resistance Guided Therapy for Mycoplasma genitalium and gonorrhoea respectively – and Plex PCR® VHS, a multiplex lesion diagnostic test.

*not available in the U.S. or Australia
§based on in silico investigation as of April 2021
†not available in the U.S.

About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. SpeeDx has a portfolio of CE-IVD kits for detection of infectious disease pathogens, sexually transmitted infection (STI), and antimicrobial resistance markers. SpeeDx ResistancePlus tests enable Resistance Guided Therapy, improving patient outcomes by empowering practitioners to make informed clinical decisions.

For more information about SpeeDx please see: http://plexpcr.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Global Marketing Director
Madeline O’Donoghue
madelineo@speedx.com.au
+61 406 582 808

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Global Strengthens Global Mobility Platform with Addition of Member Firm16.2.2026 16:30:00 EET | Press release

Andersen Global reinforces its presence in Switzerland with the addition of new member firm Exactio, bolstering its global mobility capabilities and further enhancing its integrated, multidisciplinary professional services model. Exactio provides tailored global mobility advisory and compliance services to multinational companies and internationally mobile individuals. The firm’s experienced team advises on Swiss and international tax, social security, pension, payroll, and immigration matters, supporting organizations in navigating complex employer obligations while ensuring a seamless and compliant global mobility experience. Exactio is dedicated to understanding each client’s unique needs and delivering responsive, practical solutions through a hands-on, human approach across every engagement. “At Exactio, we are committed to delivering personalized, practical, and timely solutions that enable our clients to navigate the complexities of global mobility with confidence,” said Per Mel

AIT Worldwide Logistics Announces Strategic Partnership With Greenbriar Equity Group16.2.2026 16:03:00 EET | Press release

Supply chain solutions leader AIT Worldwide Logistics (“AIT”) has entered into a definitive agreement to partner with Greenbriar Equity Group, L.P. (“Greenbriar”) in support of the global freight forwarder’s next chapter of growth. Financial terms of the private transaction were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216984391/en/ AIT Worldwide Logistics' strategic partnership with Greenbriar Equity Group represents one of the largest private acquisitions ever in the global freight forwarding sector. The deal marks the culmination of five successful years with The Jordan Company, L.P. (“TJC”). TJC, alongside key members of AIT’s executive leadership team, will remain invested in the company. Over the course of the company’s relationship with TJC, AIT has dramatically expanded its global footprint, acquired 14 businesses, and increased its gross revenue by more than 300%. The agreement with Greenbria

Transition Industries and Mexico’s CFEnergía Sign Natural Gas Supply Contract Enabling Construction of Pacifico Mexinol, the World’s Largest Ultra-Low Carbon Methanol Plant16.2.2026 15:00:00 EET | Press release

Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and hydrogen projects, and CFEnergía, a subsidiary of Mexico’s Federal Electricity Commission (CFE), announced the signing of a long-term firm natural gas supply contract for the Pacifico Mexinol (“Mexinol”) project, located near Topolobampo, Sinaloa. Under this agreement, CFEnergía will supply approximately 160 million cubic feet per day (MMcfd) of natural gas over the long term, ensuring a critical input for Mexinol’s production of ultra-low carbon methanol. The supply will be provided by CFEnergía at market prices and will optimize the use of existing infrastructure. CFEnergía will source the natural gas from the USA. The agreement is subject to customary conditions. The contract signing with CFEnergía represents the final outstanding commercial milestone, enabling the start of the construction phase, and confirming the timeline for Mexinol’s operational readiness in late 2029 to early 2030. Wh

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials16.2.2026 15:00:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ongoing Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The company will be disclosing new clinical data from Part A and Part B from COMP005 and Part A from COMP006. The results are scheduled for release on February 17th at 6:30 am ET, followed by a webinar hosted by Compass management at 8:00 am ET. Live Webcast Compass management will host a live audio webcast on February 17th at 8:00 am ET. The webcast will be accessible at this link: https://lifescievents.com/event/hz02j0rpw/ A replay of the webcast will be accessible for 30 days following the event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in m

K2 Partnering Solutions Appoints Srinivas Rao as Chief Executive Officer16.2.2026 11:00:00 EET | Press release

K2 Partnering Solutions, a global leader in consultative technology and talent solutions, today announced the appointment of Srinivas Rao as Chief Executive Officer. Srinivas is a seasoned global executive with more than 28 years of experience driving value creation, scalable growth, and operational transformation across digital, consulting, IT services, and business services. He brings deep expertise in leading complex, multi-market organisations and has successfully scaled $800M+ P&Ls, working closely with boards, sponsors, and executive leadership teams across the USA, UK, Europe, the Middle East, and APAC. Most recently, Srinivas served as Chief Business Officer and a member of the Executive Council at LTIMindtree, where he was accountable for growth acceleration, market expansion, strategic customer relationships, and operating performance across a highly complex regional footprint. During his tenure, he played a pivotal role in strengthening go-to-market execution, driving margin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye